We are dedicated to developing a safe and effective COVID-19 DNA vaccine to protect against COVID-19. Interested in participating in the Phase 1 trial for Covigenix vaccine? Please contact Heather Samson at CCfV at (902) 470-8141 to participate or go to CCfV for more information!
May 19, 2021
The Canadian Center for Vaccinology is actively seeking participants for the Phase I Trial to Evaluate Safety, Tolerability, Immunogenicity of a DNA Vaccine against SARS CoV-2 [Covigenix VAX-001] in Healthy Adults from 18 to <85 years of age.
April 15, 2021
The first recruits were dosed to start the Phase 1 trial of Entos’ made-in-Canada COVID-19 DNA vaccine, Covigenix VAX-001! Like the globally approved mRNA vaccines, Entos’ DNA vaccine delivers the information needed for our cells to make the spike protein to stimulate a protective immune response against SARS-CoV-2. However, Entos’ Covigenix DNA vaccine is more stable at fridge and room temperatures and easier to upscale and manufacture millions of doses.
“We need to get 16 billion doses worldwide to beat this pandemic, and we believe DNA is the perfect way to approach that,” said John Lewis, CEO Entos Pharmaceuticals.
Fusogenix is the ideal platform for delivery of next generation genetic therapies.
Unlike conventional lipid-based delivery, Fusogenix is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.
Fusogenix has a wide biodistribution across all organs and tissues.
Due to the unique biophysical and chemical properties of Fusogenix, a wide variety of extra-hepatic tissues can be effectively targeted at therapeutic doses. Entos has developed a panel of formulations to accurately target specific tissues.
Fusogenix uses a novel fusion mechanism to deliver its payload directly inside cells.
Our proprietary FAST (Fusion-Associated Small Transmembrane) protein technology enables fusion of the proteo-lipid vehicle with the plasma membrane of target cells. Nucleic acid cargoes are delivered intact into the cytoplasm for immediate use as a therapeutic agent.
